StockData
Merck & Co., Inc. logo

Merck & Co., Inc. (MRK) operating KPIs

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)

Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%

Merck fosamax (alendronate, legacy pre-Organon spin-off) — International sales ($M) ($M)

Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b

Latest, Q4 2018
49
Period ended Dec 31, 2018
Change on a year earlier
-21.0%
62 in Q4 2017
History
9 quarters
Since Q4 2016
Sources
5
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedFosamax (alendronate, legacy pre-Organon spin-off) — International sales ($M) ($M)Year on yearSource
Q4 2018Dec 31, 201849-21.0%Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗
Q3 2018Sep 30, 201842-12.5%Form 8-K (a18-37128_1ex99d1.htm, filed 2018-10-25) ↗
Q2 2018Jun 30, 201856-13.8%Form 8-K (a18-17779_1ex99d1.htm, filed 2018-07-27) ↗
Q1 2018Mar 31, 201857-5.0%Form 8-K (a18-12417_1ex99d1.htm, filed 2018-05-01) ↗
Q4 2017Dec 31, 201762-4.6%Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗
Q3 2017Sep 30, 201748–Form 8-K (a18-37128_1ex99d1.htm, filed 2018-10-25) ↗
Q2 2017Jun 30, 201765–Form 8-K (a18-17779_1ex99d1.htm, filed 2018-07-27) ↗
Q1 2017Mar 31, 201760–Form 8-K (a18-12417_1ex99d1.htm, filed 2018-05-01) ↗
Q4 2016Dec 31, 201665–Form 8-K (a18-5152_1ex99d1.htm, filed 2018-02-02) ↗

Breakdown

What makes up fosamax (alendronate, legacy pre-organon spin-off) — international sales ($m)

Cite this data

StockData. (2026). Merck Fosamax (alendronate, legacy pre-Organon spin-off) — International sales ($M) ($M), quarterly Q4 2016–Q4 2018 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev_fosamax_intl

See every metric in the Merck KPI table. Data updated Oct 26, 2026.